Since the 1st Korea-Japan Gynecologic Cancer Joint Meeting in Seoul, October 22, 2002 during 9th International Gynecologic Cancer Society meeting, Gynecologic Cancer Joint Meetings have been held alternatively in Korea and Japan every year until 8th meeting in Tokyo in 2009. From the 9th meeting of this year on, Gynecologic Cancer Joint Meetings between Japan and Korea are supposed to be held every other year at the same period of time as biennial meeting of Asian Society of Gynecologic Oncology (ASGO). The 9th Korea-Japan Gynecologic Cancer Joint Meeting was held in Seoul on November 3, 2011 during 2nd biennial meeting of ASGO (Fig. 1) . The agenda of the meeting is shown in Table 1 .
DISCUSSION AND FUTURE PERSPECTIVES
There are several trials proposed by Korean Gynecologic Oncology Group (KGOG). Two trials of cervical cancer were initiated by Dr. Sang Young Ryu, GOG 263, and TACO trial. GOG 263 is a randomized phase III trial of adjuvant radiation versus chemoradiation in intermediate risk, stage I/IIA cervical cancer treated with initial radical hysterectomy and pelvic lymphadenectomy. TACO (GCIG/KGOG 1027) is a randomized trial of weekly versus tri-weekly cisplatin based chemoradiation in locally advanced cervical cancer. Dr. Sokbom Kang and Professor Noriaki Sakuragi collaborated for a cross-validation study to develop preoperative criteria identifying for low-risk group of lymph node metastasis in endometrial cancer. Regarding ovarian cancer, professor Byoung-Gie Kim suggested a translational research on clear cell carcinoma, which needs consortium of several countries with high prevalence of the disease, and sharing of tissue samples and co-work between Japan, Taiwan, and Korea. Lastly, future perspectives of this KoreaJapan Joint meeting include: deepening our friendships, sharing other's scientific achievements, co-work for mutual clinical protocols, developing cancer treatment guidelines together, and exchange programs for faculties and residents. I would like to express my heartiest gratitude to Japan Gynecologic Oncology Group (JGOG) who graciously accepted our invitation to share their expertise in the field of gynecologic oncology (presented by Professor Hee-Sug Ryu). JGOG desires to work together with KGOG more closely through this Korea-Japan Gynecologic Cancer Joint Meeting. In Korea and Japan, neoadjuvant chemotherapy followed by 
